Human growth hormone is a protein hormone that promotes cell growth, reproduction, and cell differentiation in humans and many other animals. It is therefore vital for human growth. It helps maintain normal functioning of reproductive organs, controls body temperature, orchestrates cell division, orchestrates nervous system development, regulates blood pressure, and helps maintain skin elasticity. It also has effects on other body tissues such as the eyes, liver, pancreas, kidneys, stomach, and adrenal glands.
The high prevalence of chronic GH deficiency is expected to drive the growth of the global human growth hormone market. For example, according to the study “Prevalence of growth hormone deficiency in middle-aged adults recovering from stroke”, published in the journal Brain Injury, in October 2019, GHD was diagnosed in 54% of patients, 32% of whom fell into the severe category. In addition, the approval and launch of new products is also expected to contribute to the growth of the market. For example, in September 2020, the United States Food and Drug Administration approved somapacitan (Sogroya, Novo Nordisk) for endogenous growth hormone replacement in adults with growth hormone deficiency.
However, skepticism regarding over-the-counter human growth hormone claims is expected to hamper the growth of the global human growth hormone market. The use of growth hormone in children also increases the risk of cardiovascular disease in adulthood. Such side effects are also expected to limit the growth of the market.
Among the regions, Asia-Pacific is expected to experience significant growth in the global human growth hormone market, owing to the approval and launch of new products in the region. For example, in August 2020, I-Mab, a clinical-stage biopharmaceutical company, announced that the National Medicines Administration of China had accepted its pivotal trial application for eftansomatropin (also known as TJ101 ) as a weekly treatment for growth hormone deficiency in pediatric patients. .
The major players operating in the global human growth hormone market are focusing on R&D to expand their product portfolio. For example, in October 2019, OPKO Health Inc. announced that the global phase 3 trial evaluating once-weekly somatrogon in prepubertal children with growth hormone deficiency (GHD) has met its endpoint. main non-inferiority compared to GENOTROPIN (somatropin) daily. for injection, as measured by annual growth rate at 12 months.
The main players in the industry are: Pfizer Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, Novo Nordisk, Sandoz International GmbH, Ferring Holding SA and Ipsen.
LIMITED TIME OFFER – Hurry!
Exclusive offer !!! Buy the report at a reduced rate !!!
Global Human Growth Hormone Market Research Report Section 1: Global Human Growth Hormone Industry Overview Section 2: Global Economic Impact on Human Growth Hormone Industry Section 3: Competition in the world market by industry producers Section 4: World Productions, Revenue (Value), by Region Section 5: Global Supply (Production), Consumption, Export, Import, Geographically Section 6: World Productions, Revenue (Value), Price Trend, Product Type Section 7: Global Market Analysis, Based on Application Section 8: Market Price Analysis of Human Growth Hormone Section 9: Market Chain, Sourcing Strategy and Downstream Buyers Section 10: Key Distributor / Supplier / Dealer Strategies and Policies Section 11: Analysis of Key Marketing Strategy, by Market Suppliers Section 12: Analysis of Market Effect Factors Section 13: Global Human Growth Hormone Market Forecast